You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 125 No. 4, April 2007 TABLE OF CONTENTS
  Archives
  •  Online Features
  Laboratory Sciences
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (3)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Aging/ Geriatrics
 •Macular Degeneration
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Estimation of Systemic Complement C3 Activity in Age-Related Macular Degeneration

Sobha Sivaprasad, FRCS; Temi Adewoyin, MRCOphth; Tracey A. Bailey, PhD; Sam S. Dandekar, FRCOphth; Sharon Jenkins, MSc; Andrew R. Webster, FRCOphth; Ngaihang Victor Chong, FRCOphth

Arch Ophthalmol. 2007;125(4):515-519.

Objectives  To determine the role of systemic complement activation in the pathogenesis of age-related macular degeneration and to examine whether serum C3a des Arg reflects systemic complement activation, independent of individual complement component levels.

Methods  Plasma complement C3a des Arg levels and a single nucleotide polymorphism at position 402 of the complement factor H gene (CFH) were determined in 3 groups of subjects: 42 subjects with early age-related maculopathy, 42 subjects with neovascular (wet) age-related macular degeneration, and a control group of 38 subjects with no clinical evidence of age-related changes at the macula.

Results  The median (range) of plasma complement C3a des Arg levels in the age-related maculopathy and neovascular age-related macular degeneration groups were 52.6 (2.8-198.1) ng/mL and 60.9 (3.1-173.1) ng/mL, respectively. The levels were significantly raised compared with the control group (n = 38), which had a median (range) plasma complement C3a des Arg level of 40.3 (6.1-81.7) ng/mL (analysis of variance, P = .02). The concentration of plasma C3a des Arg did not differ significantly between those with different CFH genotypes (P = .07).

Conclusion  Systemic activation of the complement system may contribute to the pathogenesis of age-related macular degeneration independent of CFH polymorphism.

Clinical Relevance  The results of this study may be relevant to aiming new treatment strategies toward reducing systemic low-grade inflammation.


Author Affiliations: Laser and Retinal Research Unit, King's College Hospital, King's College London (Drs Sivaprasad, Adewoyin, and Chong), Moorfields Eye Hospital (Drs Sivaprasad, Dandekar, and Webster, and Ms Jenkins), and Institute of Ophthalmology, University College London (Drs Dandekar, Webster, and Chong and Ms Jenkins), London, England; and Cranfield BioMedical Centre, Cranfield University at Silsoe, Bedfordshire, England (Drs Sivaprasad and Bailey).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Functional basis of protection against age-related macular degeneration conferred by a common polymorphism in complement factor B
Montes et al.
Proc. Natl. Acad. Sci. USA 2009;106:4366-4371.
ABSTRACT | FULL TEXT  

Complement factor H deficiency in aged mice causes retinal abnormalities and visual dysfunction
Coffey et al.
Proc. Natl. Acad. Sci. USA 2007;104:16651-16656.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2007 American Medical Association. All Rights Reserved.